MDM2 gene polymorphisms and risk of classic Kaposi’s sarcoma among Iranian patients

Abstract

A single-nucleotide polymorphism (SNP) in the promoter region of MDM2 (SNP309T>G, rs2279744) has been shown to increase the expression of the MDM2 protein in various cancer types. However, only one study has analyzed the role of the MDM2 polymorphism in the development of Kaposi's sarcoma (KS). The association of MDM2 SNP309 with classic KS risk was evaluated in 79 Iranian patients with classic KS and 123 healthy controls. The MDM2 SNP309 was genotyped using PCR and restriction fragment length polymorphism methods. No significant correlation was found between the SNP309 polymorphism in MDM2 promoter and classic KS risk. There was no significant correlation between gender and disease stage. However, a significant association was found between SNP309 GG genotype and younger age (≤50 years) (odds ratio 9.5, 95% confidence intervals 1.5-60, p = 0.03). Our findings support no major role for the MDM2 SNP309 in KS development although it might influence the clinical outcome of KS in younger patients.

Association of Murine Double Minute 2 polymorphisms with gastric cancer: A systematic review with meta‑analysis

“…Some studies have shown that MDM2 amplification occurs in GC, with an expected impact on p53 pathways (12,13). Furthermore, similar to what has been described for other types of cancer (14)(15)(16)(17)(18)(19), MDM2 polymorphisms that can lead to differential protein activity may have an impact on GC susceptibility (20)(21)(22)(23).…”

A case‐control study on the SNP309T → G and 40‐bp Del1518 of theMDM2gene and a systematic review forMDM2polymorphisms in the patients with breast cancer

“…and other types of cancer, such as endometrial, 44 bladder, 45 esophageal squamous cell, 41 Kaposi's sarcoma, 56 and uterine leiomyomas. 43 However, in several studies, an association has been reported between the SNP309 polymorphism and the incidence of BC worldwide.…”

“…Also, Zhao et al (2012) in a meta‐analysis reported no significant correlation between the MDM2 ‐SNP309 and the incidence of BC in the European populations 12 . A negative association has been confirmed between the MDM2 ‐SNP309 and other types of cancer, such as endometrial, 44 bladder, 45 esophageal squamous cell, 41 Kaposi's sarcoma, 56 and uterine leiomyomas 43 . However, in several studies, an association has been reported between the SNP309 polymorphism and the incidence of BC worldwide 10,11,14,18,23,57‐59 …”

Evidence for altered host genetic factors in KSHV infection and KSHV‐related disease development

“…Risk of classic KS is threefold higher in men from the South of Italy than the North 35 . Transplant recipients of Mediterranean, Jewish and Middle Eastern ancestry (at risk for classic KS) are also overrepresented among iatrogenic KS patients regardless of their residence at the time of the transplant 19,35,36 . Among HIV‐positive patients, risk of developing AIDS‐KS is reported to be higher in South Africa than in Europe, North America and Latin America and the trend of decreased risk concomitant with increased CD4 count after initiation of ART evident in these regions was not observed in South Africa 22 .…”

“…35 Transplant recipients of Mediterranean, Jewish and Middle Eastern ancestry (at risk for classic KS) are also overrepresented among iatrogenic KS patients regardless of their residence at the time of the transplant. 19,35,36 Among HIV-positive patients, risk of developing AIDS-KS is reported to be higher in South Africa than in Europe, North America and Latin America and the trend of decreased risk concomitant with increased CD4 count after initiation of ART evident in these regions was not observed in South Africa. 22 Geographic and population-specific prevalence of KSHV and incidence of KS suggest a potential role for host genetic factors in susceptibility to KSHV infection and subsequent development of KS.…”